Simpson Thacher represented Amneal Pharmaceuticals, Inc. (“Amneal”) in connection with a series of transactions involving Amneal and certain of its subsidiaries which resulted in the elimination of Amneal’s umbrella partnership – C corporation (“Up-C”) structure and simplified its equity capital structure to a single class of common stock.~~Amneal (NYSE: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business, as well as deepening portfolios in institutional injectables, biosimilars and select international markets.~~The Simpson Thacher team included Richard Fenyes, Anna Jarman and Emily Anne Owen (Capital Markets); Karen Kelley, Jennifer Nadborny and Bettina Elstroth (Public Company Advisory Practice); Andrew Purcell and Tova Pfeffer (Tax); Jakob Rendtorff (M&A); and Jamin Koslowe (Executive Compensation and Employee Benefits).